2012
DOI: 10.1158/1055-9965.epi-12-0173
|View full text |Cite
|
Sign up to set email alerts
|

The Oncogenic Role of miR-155 in Breast Cancer

Abstract: miR-155 is an oncogenic miRNA with well described roles in leukemia. However, additional roles of miR-155 in breast cancer progression have recently been described. A thorough literature search was conducted to review all published data to date, examining the role of miR-155 in breast cancer. Data on all validated miR-155 target genes was collated to identify biologic pathways relevant to miR-155 and breast cancer progression. Publications describing the clinical relevance, functional characterization, and reg… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

10
162
0
4

Year Published

2013
2013
2024
2024

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 257 publications
(176 citation statements)
references
References 88 publications
10
162
0
4
Order By: Relevance
“…[6][7][8][9] Sustained proliferation is a hallmark of transformed cells. Knockdown of BIC in malignant MyLa2059 cells entailed a 40% decrease of miR-155 expression (Fig.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…[6][7][8][9] Sustained proliferation is a hallmark of transformed cells. Knockdown of BIC in malignant MyLa2059 cells entailed a 40% decrease of miR-155 expression (Fig.…”
Section: Resultsmentioning
confidence: 99%
“…It has been found overexpressed in hematological 4,5 as well as a number of solid cancers. [6][7][8][9] miR-155 is localized within an exon of its precursor gene BIC (B cell integration cluster or pri-miR-155). 4 Transiently elevated expression of miR-155 plays a role in the activation of several types of immune cells, 2,[10][11][12] whereas constitutively high levels of this miRNA can result in the development of malignancies by increase of genomic instability 13,14 and sustained proliferation and survival 5,15 of malignant cells.…”
Section: Introductionmentioning
confidence: 99%
“…The miR155 also has opposite actions, it can be oncogenic (the targets are BCL2, FOXO3a, RhoA) or tumor suppressor (the targets are TGF-beta/SMAD) [158]. The literature about miR155 is vast, and we suggest the articles by Higgs and Slack [158] and Mattiske et al [159] for a deep reading. Besides these two miRNAs cited above, others miRNAs are upregulated by ROS, such as miR23, miR200, miR210, etc., affecting migration, invasion; tumor growth, angiogenesis; cell cycle, DNA damage (among others), respectively [126].…”
Section: Some Ros Such As Omentioning
confidence: 97%
“…Other targets of miR-21 includes PTEN in hepatocellular carcinoma (49); tumor suppressor genes ANP32A (nuclear phosphoprotein 32 family, member A/alias pp32/ LANP) in human prostate carcinoma cells, and SMARCA4 (alias BRG1) in B-cell lymphoma (50); maspin, a tumor suppressor in invasion and metastasis (51), and tropomyosin 1 (TPM1) in breast cancer MCF-7 cells (52). Another miRNA acting as an oncogene is miR-155 whose role in breast cancer progression has been studied recently (53). It is highly upregulated in breast cancer where it targets tumor suppressor gene SOCS1 (54).…”
Section: Oncomirsmentioning
confidence: 99%